Does Dr. REBEKAH GENSURE have financial conflicts of interest?

Dr. REBEKAH GENSURE (M.D., PH.D.) has received a total of $4,342 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $4,342 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. REBEKAH GENSURE?

According to CMS Open Payments data, Dr. REBEKAH GENSURE received funding from APELLIS PHARMACEUTICALS ($3,158), GENENTECH USA ($410), and BIOGEN ($138).

Does Dr. REBEKAH GENSURE receive research grants or speaking fees?

Dr. REBEKAH GENSURE has received $4,342 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. REBEKAH GENSURE

M.D., PH.D.Real-Time Hydrated

Specialty: Ophthalmology, Retina Specialist

Practice Location: SALT LAKE CITY, UT 84107

NPI Number: 1225490444

LIFETIME INDUSTRY VALUE

$4,342

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GENSURE is a verified Ophthalmology, Retina Specialist practitioner based in SALT LAKE CITY, UT.

Between 2021 and 2025, Dr. GENSURE had an overall industry promotional and research financial footprint of $4,342 as recorded in the federal CMS Open Payments database.

$4,342 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. GENSURE's primary funding source is APELLIS PHARMACEUTICALS, which accounts for $3,158 (representing 72.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

APELLIS PHARMACEUTICALS

Rank 1

$3,158

72.7%

GENENTECH USA

Rank 2

$410

9.4%

BIOGEN

Rank 3

$138

3.2%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.